What's Happening?
Novotech, a globally recognized full-service biotech clinical research organization (CRO), has appointed Dr. Anand Tharmaratnam as its new Chief Executive Officer. Dr. Tharmaratnam, who has been with Novotech as Chairman
since 2021, assumed the role of CEO on January 1, 2026. He brings nearly three decades of experience in the global CRO industry, having previously worked with Quintiles and its successor IQVIA. His appointment follows the decision of former CEO Dr. John Moller to step down after nine years, a move that coincided with the successful completion of a capital raising initiative in March 2025. This initiative brought in new investors, including GIC and Temasek, alongside long-term supporter TPG. Dr. Tharmaratnam will be based at Novotech's new global headquarters in Singapore, reflecting the company's increasingly international profile.
Why It's Important?
The appointment of Dr. Tharmaratnam as CEO is significant as it marks a new phase of growth and global expansion for Novotech. With his extensive experience and leadership, the company is poised to strengthen its position as a leading biotech CRO in the Asia-Pacific region and beyond. The involvement of major investors like GIC, Temasek, and TPG underscores confidence in Novotech's strategic direction and potential for growth. This leadership change is expected to enhance Novotech's capabilities in clinical research, enabling it to deliver innovative solutions and support complex biotech programs globally. The company's expansion efforts are likely to have a positive impact on the biotech industry, facilitating the development and market entry of life-changing therapies.
What's Next?
Under Dr. Tharmaratnam's leadership, Novotech plans to expand its global footprint and strengthen its scientific capabilities. The company aims to leverage technology and data to support increasingly global and complex biotech programs. Novotech's focus will remain on delivering impactful and innovative outcomes for clients, helping to advance future medicines. The company is also expected to continue its collaboration with key clinical trial destinations and diverse patient populations, further enhancing its service offerings. As Novotech enters this new phase, it will likely explore new markets and partnerships to drive its growth and maintain its competitive edge in the biotech CRO industry.
